SK1502002A3 - A polynucleotide, a vector, a host cell, method for producing molecular variant mdr-1 protein, mdr-1 protein, an antibody, a nucleic acid molecule and a transgenic animal containing the same and the use thereof - Google Patents

A polynucleotide, a vector, a host cell, method for producing molecular variant mdr-1 protein, mdr-1 protein, an antibody, a nucleic acid molecule and a transgenic animal containing the same and the use thereof Download PDF

Info

Publication number: SK1502002A3
Authority: SK; Slovakia
Prior art keywords: mdr; artificial sequence; gene; dna; synthetic
Prior art date: 1999-07-30

Application number

SK150-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Ulrich Brinkmann

Sven Hoffmeyer

Michel Eichelbaum

Ivar Roots

Original Assignee

Epidauros Biotechnologie Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-30

Filing date

2000-07-28

Publication date

2002-07-02

2000-07-28 Application filed by Epidauros Biotechnologie Ag filed Critical Epidauros Biotechnologie Ag

2002-07-02 Publication of SK1502002A3 publication Critical patent/SK1502002A3/sk

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 303
102000004169 proteins and genes Human genes 0.000 title claims abstract description 110
102000040430 polynucleotide Human genes 0.000 title claims abstract description 92
108091033319 polynucleotide Proteins 0.000 title claims abstract description 92
239000002157 polynucleotide Substances 0.000 title claims abstract description 92
239000013598 vector Substances 0.000 title claims abstract description 49
230000009261 transgenic effect Effects 0.000 title claims abstract description 17
238000004519 manufacturing process Methods 0.000 title claims abstract description 8
150000007523 nucleic acids Chemical class 0.000 title claims description 34
102000039446 nucleic acids Human genes 0.000 title claims description 28
108020004707 nucleic acids Proteins 0.000 title claims description 28
241001465754 Metazoa Species 0.000 title claims description 15
238000000034 method Methods 0.000 claims abstract description 145
239000003814 drug Substances 0.000 claims abstract description 77
230000014509 gene expression Effects 0.000 claims abstract description 74
229940079593 drug Drugs 0.000 claims abstract description 70
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
239000003112 inhibitor Substances 0.000 claims abstract description 37
239000000758 substrate Substances 0.000 claims abstract description 25
208000035475 disorder Diseases 0.000 claims abstract description 24
239000000203 mixture Substances 0.000 claims abstract description 24
210000004027 cell Anatomy 0.000 claims description 84
108700028369 Alleles Proteins 0.000 claims description 66
239000012634 fragment Substances 0.000 claims description 50
230000000694 effects Effects 0.000 claims description 48
239000002773 nucleotide Substances 0.000 claims description 40
125000003729 nucleotide group Chemical group 0.000 claims description 40
150000001875 compounds Chemical class 0.000 claims description 32
108090000765 processed proteins & peptides Proteins 0.000 claims description 25
102000004196 processed proteins & peptides Human genes 0.000 claims description 22
238000006467 substitution reaction Methods 0.000 claims description 21
238000011282 treatment Methods 0.000 claims description 21
239000000523 sample Substances 0.000 claims description 20
229920001184 polypeptide Polymers 0.000 claims description 19
206010028980 Neoplasm Diseases 0.000 claims description 17
150000001413 amino acids Chemical class 0.000 claims description 16
108091034117 Oligonucleotide Proteins 0.000 claims description 13
125000003275 alpha amino acid group Chemical group 0.000 claims description 13
201000011510 cancer Diseases 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 12
230000036765 blood level Effects 0.000 claims description 11
238000012217 deletion Methods 0.000 claims description 11
230000037430 deletion Effects 0.000 claims description 11
238000003205 genotyping method Methods 0.000 claims description 11
238000009396 hybridization Methods 0.000 claims description 11
239000000126 substance Substances 0.000 claims description 11
230000001225 therapeutic effect Effects 0.000 claims description 10
230000036457 multidrug resistance Effects 0.000 claims description 9
230000002974 pharmacogenomic effect Effects 0.000 claims description 9
239000000651 prodrug Substances 0.000 claims description 9
229940002612 prodrug Drugs 0.000 claims description 9
238000012546 transfer Methods 0.000 claims description 8
230000003321 amplification Effects 0.000 claims description 7
230000000295 complement effect Effects 0.000 claims description 7
238000003199 nucleic acid amplification method Methods 0.000 claims description 7
238000012163 sequencing technique Methods 0.000 claims description 7
230000004044 response Effects 0.000 claims description 6
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 5
210000003527 eukaryotic cell Anatomy 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
229930105110 Cyclosporin A Natural products 0.000 claims description 4
108010036949 Cyclosporine Proteins 0.000 claims description 4
229960001265 ciclosporin Drugs 0.000 claims description 4
238000003018 immunoassay Methods 0.000 claims description 4
239000000411 inducer Substances 0.000 claims description 4
210000001236 prokaryotic cell Anatomy 0.000 claims description 4
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical group C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 3
208000024172 Cardiovascular disease Diseases 0.000 claims description 3
101150066553 MDR1 gene Proteins 0.000 claims description 3
239000001961 anticonvulsive agent Substances 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
238000012377 drug delivery Methods 0.000 claims description 3
238000007834 ligase chain reaction Methods 0.000 claims description 3
230000001404 mediated effect Effects 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
229960001722 verapamil Drugs 0.000 claims description 3
SVJMLYUFVDMUHP-MGBGTMOVSA-N (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[3-(4,4-diphenyl-1-piperidinyl)propyl] ester O3-methyl ester Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-MGBGTMOVSA-N 0.000 claims description 2
206010013710 Drug interaction Diseases 0.000 claims description 2
YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
230000000573 anti-seizure effect Effects 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
229940097217 cardiac glycoside Drugs 0.000 claims description 2
239000002368 cardiac glycoside Substances 0.000 claims description 2
208000015114 central nervous system disease Diseases 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
229950002422 dexniguldipine Drugs 0.000 claims description 2
230000029087 digestion Effects 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
229940124589 immunosuppressive drug Drugs 0.000 claims description 2
239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
229930002534 steroid glycoside Natural products 0.000 claims description 2
150000008143 steroidal glycosides Chemical class 0.000 claims description 2
230000002194 synthesizing effect Effects 0.000 claims description 2
229950010938 valspodar Drugs 0.000 claims description 2
108010082372 valspodar Proteins 0.000 claims description 2
206010029216 Nervousness Diseases 0.000 claims 1
102100030306 TBC1 domain family member 9 Human genes 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
102000054767 gene variant Human genes 0.000 claims 1
238000002331 protein detection Methods 0.000 claims 1
201000010099 disease Diseases 0.000 abstract description 15
230000002159 abnormal effect Effects 0.000 abstract description 4
238000001228 spectrum Methods 0.000 abstract description 4
238000002560 therapeutic procedure Methods 0.000 abstract description 4
206010059866 Drug resistance Diseases 0.000 abstract description 3
230000007257 malfunction Effects 0.000 abstract description 3
108020004414 DNA Proteins 0.000 description 400
238000003752 polymerase chain reaction Methods 0.000 description 41
230000000875 corresponding effect Effects 0.000 description 38
102000054765 polymorphisms of proteins Human genes 0.000 description 28
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 24
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 24
229960005156 digoxin Drugs 0.000 description 24
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 24
239000013615 primer Substances 0.000 description 24
210000004369 blood Anatomy 0.000 description 23
239000008280 blood Substances 0.000 description 23
108700024394 Exon Proteins 0.000 description 20
239000003153 chemical reaction reagent Substances 0.000 description 18
238000003556 assay Methods 0.000 description 17
230000035772 mutation Effects 0.000 description 17
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 17
229960001225 rifampicin Drugs 0.000 description 17
108091028043 Nucleic acid sequence Proteins 0.000 description 14
238000004458 analytical method Methods 0.000 description 12
230000001105 regulatory effect Effects 0.000 description 12
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 11
229960002036 phenytoin Drugs 0.000 description 11
239000000047 product Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
241000282412 Homo Species 0.000 description 10
230000001419 dependent effect Effects 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
238000013459 approach Methods 0.000 description 8
210000000936 intestine Anatomy 0.000 description 8
230000002441 reversible effect Effects 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
238000012300 Sequence Analysis Methods 0.000 description 7
238000001514 detection method Methods 0.000 description 7
238000003745 diagnosis Methods 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
238000000746 purification Methods 0.000 description 7
238000007792 addition Methods 0.000 description 6
238000000137 annealing Methods 0.000 description 6
238000004925 denaturation Methods 0.000 description 6
230000036425 denaturation Effects 0.000 description 6
238000009826 distribution Methods 0.000 description 6
239000003623 enhancer Substances 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
108091092562 ribozyme Proteins 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
108090000994 Catalytic RNA Proteins 0.000 description 5
102000053642 Catalytic RNA Human genes 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000000306 component Substances 0.000 description 5
238000013461 design Methods 0.000 description 5
230000000968 intestinal effect Effects 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000000816 peptidomimetic Substances 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
238000002405 diagnostic procedure Methods 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
108010006785 Taq Polymerase Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000004075 alteration Effects 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004590 computer program Methods 0.000 description 3
230000000857 drug effect Effects 0.000 description 3
238000002651 drug therapy Methods 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
239000002987 primer (paints) Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000533845 Enterolobium cyclocarpum Species 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
KYFGGRHWLFZXPU-KKUMJFAQSA-N His-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N KYFGGRHWLFZXPU-KKUMJFAQSA-N 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
WXDRGWBQZIMJDE-ULQDDVLXSA-N Leu-Phe-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O WXDRGWBQZIMJDE-ULQDDVLXSA-N 0.000 description 2
NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 2
108700041567 MDR Genes Proteins 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
241000700159 Rattus Species 0.000 description 2
TVPQRPNBYCRRLL-IHRRRGAJSA-N Ser-Phe-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O TVPQRPNBYCRRLL-IHRRRGAJSA-N 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
241000700605 Viruses Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
-1 antibodies Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
239000003118 drug derivative Substances 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
210000001842 enterocyte Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
108010079502 exoribonuclease T Proteins 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
238000010363 gene targeting Methods 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
108010020532 tyrosyl-proline Proteins 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
238000001262 western blot Methods 0.000 description 2
JKMPXGJJRMOELF-UHFFFAOYSA-N 1,3-thiazole-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=C(C(O)=O)S1 JKMPXGJJRMOELF-UHFFFAOYSA-N 0.000 description 1
SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
101150037123 APOE gene Proteins 0.000 description 1
102220468397 ATP-dependent translocase ABCB1_N21D_mutation Human genes 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
244000105975 Antidesma platyphyllum Species 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
101150094690 GAL1 gene Proteins 0.000 description 1
102100028501 Galanin peptides Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
241000208680 Hamamelis mollis Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 1
101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
101000799388 Homo sapiens Thiopurine S-methyltransferase Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
238000010357 RNA editing Methods 0.000 description 1
230000026279 RNA modification Effects 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
241000220317 Rosa Species 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102100034162 Thiopurine S-methyltransferase Human genes 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
101150046432 Tril gene Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000007844 allele-specific PCR Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
235000021028 berry Nutrition 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000004568 cement Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000013098 chemical test method Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000010219 correlation analysis Methods 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003107 drug analog Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
210000002980 germ line cell Anatomy 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010440 gypsum Substances 0.000 description 1
229910052602 gypsum Inorganic materials 0.000 description 1
235000009424 haa Nutrition 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000013115 immunohistochemical detection Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000012623 in vivo measurement Methods 0.000 description 1
238000010249 in-situ analysis Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012533 medium component Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
108700025694 p53 Genes Proteins 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000009120 phenotypic response Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
229940121649 protein inhibitor Drugs 0.000 description 1
239000012268 protein inhibitor Substances 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000004088 simulation Methods 0.000 description 1
238000011895 specific detection Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940118846 witch hazel Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Zoology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Cardiology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Pathology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)

SK150-2002A 1999-07-30 2000-07-28 A polynucleotide, a vector, a host cell, method for producing molecular variant mdr-1 protein, mdr-1 protein, an antibody, a nucleic acid molecule and a transgenic animal containing the same and the use thereof SK1502002A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP99114938		1999-07-30
EP00103361		2000-02-22
PCT/EP2000/007314 WO2001009183A2 (en)	1999-07-30	2000-07-28	Polymorphisms in the human mdr-1 gene and applications thereof

Publications (1)

Publication Number	Publication Date
SK1502002A3 true SK1502002A3 (en)	2002-07-02

Family

ID=26070560

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK150-2002A SK1502002A3 (en)	1999-07-30	2000-07-28	A polynucleotide, a vector, a host cell, method for producing molecular variant mdr-1 protein, mdr-1 protein, an antibody, a nucleic acid molecule and a transgenic animal containing the same and the use thereof

Country Status (20)

Country	Link
US (1)	US20050227249A1 (de)
EP (1)	EP1232260B1 (de)
JP (2)	JP2003510021A (de)
KR (1)	KR100814188B1 (de)
AT (1)	ATE373710T1 (de)
AU (1)	AU1131901A (de)
BG (1)	BG65988B1 (de)
CA (2)	CA2376666C (de)
CZ (1)	CZ2002329A3 (de)
DE (1)	DE60036487T2 (de)
DK (1)	DK1232260T3 (de)
EE (1)	EE200200049A (de)
ES (1)	ES2292481T3 (de)
HR (1)	HRP20020093B1 (de)
HU (1)	HUP0201997A3 (de)
MX (1)	MXPA02001094A (de)
NO (2)	NO330680B1 (de)
PL (1)	PL354034A1 (de)
SK (1)	SK1502002A3 (de)
WO (1)	WO2001009183A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001231550A1 (en) *	2000-11-29	2002-06-11	Epidauros Biotechnologie Ag	Use of mdr-1 inducers for treating or preventing diseases
AU2001226701A1 (en) *	2000-11-29	2002-06-11	Epidauros Biotechnologie Ag	Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism
AU2002249946C1 (en)	2001-01-12	2009-09-24	Washington State University	mdr1 variants and methods for their use
WO2003025174A2 (en) *	2001-09-06	2003-03-27	Bayer Healthcare Ag	Regulation of human mrp1-like protein
EP1340818A1 (de) *	2002-02-27	2003-09-03	Epigenomics AG	Verfahren und Nukleinsäuren zur Analyse von Kolonkrebszellen
WO2004042081A1 (de) *	2002-11-04	2004-05-21	Charité-Universitätsme Dizin Berlin	Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie
EP1756310B1 (de)	2004-05-12	2012-12-05	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Verfahren zur Bestimmung von Polymorphismen im ABCB1 Gen, die mit dem Fehlen einer klinischen Reaktion auf im ZNS aktiven Arzneimittel assoziert sind, und Arzneimittel, das einen ABCB1 Inhibitor enthält zur Behandlung von Krankheiten im ZNS
EP1896614A1 (de) *	2005-06-13	2008-03-12	F. Hoffmann-La Roche Ag	MDRl-SNP BEI AKUTER ZURÜCKWEISUNG
US20100092947A1 (en) *	2005-06-13	2010-04-15	Laurent Essioux	Impdh2 snp associated with acute rejection
WO2006133840A1 (en) *	2005-06-13	2006-12-21	F.Hoffmann-La Roche Ag	Il10 snp associated with acute rejection
US20090325156A1 (en) *	2005-11-10	2009-12-31	Government of the United States of America, as Represented by Secretary, Dept. of Human Services	Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
EP2520670B1 (de)	2007-06-12	2014-02-26	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Neue Polymorphismen bei ABCB1, die mit einem Mangel an klinischen Reaktionen auf Medikamente susammenhören
KR101033840B1 (ko) *	2011-03-08	2011-05-16	(주)제일엔지니어링건축사사무소	공동주택용 입상관 연결구조
US20180365372A1 (en) *	2017-06-19	2018-12-20	Jungla Inc.	Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683202A (en) *	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
CA1284931C (en) *	1986-03-13	1991-06-18	Henry A. Erlich	Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5206352A (en) *	1986-03-28	1993-04-27	Board Of Trustees Of The University Of Illinois	Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
US5928637A (en) *	1987-06-16	1999-07-27	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Methods of inducing multidrug resistance using human MDR1 cDNA
US5851819A (en) *	1987-06-16	1998-12-22	National Institutes Of Health	Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells
JPH02100680A (ja) *	1988-10-05	1990-04-12	Suntory Ltd	ヒト正常細胞由来ｍｄｒ関連遺伝子
US5399483A (en) *	1989-03-30	1995-03-21	Suntory Limited	Expression of MDR-related gene in yeast cell
US5856104A (en) *	1996-10-28	1999-01-05	Affymetrix, Inc.	Polymorphisms in the glucose-6 phosphate dehydrogenase locus
US5830697A (en) *	1997-01-21	1998-11-03	The Board Of Trustees Of The Leland Stanford Junior University	P-glycoprotein mutant resistant to cyclosporin modulation

2000
- 2000-07-28 AU AU11319/01A patent/AU1131901A/en not_active Abandoned
- 2000-07-28 DE DE60036487T patent/DE60036487T2/de not_active Expired - Lifetime
- 2000-07-28 JP JP2001513989A patent/JP2003510021A/ja active Pending
- 2000-07-28 PL PL00354034A patent/PL354034A1/xx unknown
- 2000-07-28 EP EP00972654A patent/EP1232260B1/de not_active Expired - Lifetime
- 2000-07-28 WO PCT/EP2000/007314 patent/WO2001009183A2/en not_active Ceased
- 2000-07-28 DK DK00972654T patent/DK1232260T3/da active
- 2000-07-28 CZ CZ2002329A patent/CZ2002329A3/cs unknown
- 2000-07-28 SK SK150-2002A patent/SK1502002A3/sk unknown
- 2000-07-28 ES ES00972654T patent/ES2292481T3/es not_active Expired - Lifetime
- 2000-07-28 HU HU0201997A patent/HUP0201997A3/hu unknown
- 2000-07-28 HR HR20020093A patent/HRP20020093B1/xx not_active IP Right Cessation
- 2000-07-28 AT AT00972654T patent/ATE373710T1/de active
- 2000-07-28 CA CA2376666A patent/CA2376666C/en not_active Expired - Lifetime
- 2000-07-28 CA CA2697207A patent/CA2697207A1/en not_active Abandoned
- 2000-07-28 MX MXPA02001094A patent/MXPA02001094A/es active IP Right Grant
- 2000-07-28 KR KR1020027001248A patent/KR100814188B1/ko not_active Expired - Fee Related
- 2000-07-28 EE EEP200200049A patent/EE200200049A/xx unknown
2002
- 2002-01-29 NO NO20020470A patent/NO330680B1/no not_active IP Right Cessation
- 2002-01-29 BG BG106362A patent/BG65988B1/bg unknown
2004
- 2004-10-14 US US10/965,348 patent/US20050227249A1/en not_active Abandoned
2010
- 2010-06-02 NO NO20100798A patent/NO20100798L/no unknown
2011
- 2011-01-24 JP JP2011011834A patent/JP2011142909A/ja active Pending

Also Published As

Publication number	Publication date
HUP0201997A3 (en)	2005-01-28
CA2697207A1 (en)	2001-02-08
US20050227249A1 (en)	2005-10-13
JP2003510021A (ja)	2003-03-18
EP1232260B1 (de)	2007-09-19
HRP20020093B1 (en)	2011-02-28
NO330680B1 (no)	2011-06-06
NO20020470D0 (no)	2002-01-29
NO20100798L (no)	2002-03-26
CZ2002329A3 (cs)	2002-07-17
EP1232260A2 (de)	2002-08-21
WO2001009183A3 (en)	2002-03-28
CA2376666A1 (en)	2001-02-08
KR20020059347A (ko)	2002-07-12
HRP20020093A2 (en)	2004-06-30
AU1131901A (en)	2001-02-19
PL354034A1 (en)	2003-12-15
ATE373710T1 (de)	2007-10-15
EE200200049A (et)	2003-04-15
CA2376666C (en)	2010-05-25
MXPA02001094A (es)	2003-07-21
DE60036487D1 (de)	2007-10-31
JP2011142909A (ja)	2011-07-28
NO20020470L (no)	2002-03-26
DE60036487T2 (de)	2008-06-19
BG106362A (bg)	2002-09-30
WO2001009183A2 (en)	2001-02-08
HUP0201997A2 (en)	2002-09-28
KR100814188B1 (ko)	2008-03-17
ES2292481T3 (es)	2008-03-16
BG65988B1 (bg)	2010-08-31
DK1232260T3 (da)	2008-02-04

Legal Events

Date	Code	Title	Description
2010-12-07	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
JP2011142909A (ja)	2011-07-28	ヒトｍｄｒ−１遺伝子における多型および、診断的および治療的適用におけるその使用
US20110131671A1 (en)	2011-06-02	Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8 and their use in diagnostic and therapeutic applications
EP1088900A1 (de)	2001-04-04	Polymorphismen des menschlichen CYP3A4, CYP3A7 und hPXR Gene, und ihre Anwendung in Diagnose und Therapie
US7407756B2 (en)	2008-08-05	Methods for detecting mutations associated with familial dysautonomia
US20090018030A1 (en)	2009-01-15	Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications
WO2003097873A2 (en)	2003-11-27	Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
US20060078879A1 (en)	2006-04-13	Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
US20090311696A1 (en)	2009-12-17	Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications
WO2003014387A2 (en)	2003-02-20	Polymorphisms in the human gene for cyp1a2 and their use in diagnostic and therapeutic applications
US6395488B1 (en)	2002-05-28	Cholecystokinin (CCK) gene as a risk factor for smoking in women